Viewing data from:

REPAGLINIDE

ANDA

REPAGLINIDE | A078555 | CHARTWELL RX SCIENCES LLC

3 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.0917

per ea

Lowest NADAC/Unit

$0.0761

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
62135094890REPAGLINIDE 2 MG TABLET	$0.0917	EA	Generic	—	2026-06-17
62135094790REPAGLINIDE 1 MG TABLET	$0.0887	EA	Generic	—	2026-06-17
62135094690REPAGLINIDE 0.5 MG TABLET	$0.0761	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain11 active DMFs5 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDREPAGLINIDE

DMF 172452004

SUN PHARMACEUTICAL INDUSTRIES LTDREPAGLINIDE USP

DMF 178252004

USV PRIVATE LTDREPAGLINIDE USP

DMF 183292005

BIOCON LTDREPAGLINIDE

DMF 184822005

BOEHRINGER INGELHEIM PHARMA GMBH AND CO KGREPAGLINIDE

DMF 196202006

MACLEODS PHARMACEUTICALS LTDREPAGLINIDE

DMF 222342008

APITORIA PHARMA PRIVATE LTDREPAGLINIDE USP (NON-STERILE DRUG SUBSTANCE)

DMF 230682009

JUBILANT BIOSYS LTDREPAGLINIDE USP

DMF 245192011

TORRENT PHARMACEUTICALS LTDREPAGLINIDE

DMF 256632012

CHROMO LABORATORIES INDIA PRIVATE LTDREPAGLINIDE USP

DMF 263962012

TIANJIN PHARMACEUTICAL HOLDINGS GENCOM PHARMACY CO LTDREPAGLINIDE

DMF 299222015

CHEMWERTH INCInactiveREPAGLINIDE USP

DMF 180032005

RANBAXY LABORATORIES LTDInactiveREPAGLINIDE USP

DMF 190102005

ZHEJIANG HISOAR PHARMACEUTICAL CO LTDInactiveREPAGLINIDE

DMF 209992007

ZAKLADY FARMACEUTYCZNE POLPHARMA SAInactiveREPAGLINIDE

DMF 211492007

ASYMCHEM LIFE SCIENCE TIANJIN CO LTDInactiveREPAGLINIDE

DMF 288382014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 0.5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 22, 2013

No patent or exclusivity listings for this strength.

#002 — 1MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 22, 2014

#003 — 2MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 22, 2014